Doral mayor calls potential PGA Tour return to Trump National "extraordinary"
"The return of the PGA Tour to Doral would be an extraordinary moment, bringing the tournament back to where it truly belongs," Fraga said.
Trump National Doral Golf Club, which hosted PGA Tour events for more than 50 years before its removal from the schedule in 2016, is expected to rejoin the tour's calendar after nearly a decade-long absence.
Fraga emphasized the role of the tournament in Doral's history and development.
"Golf has always been at the heart of our city's story, and for decades, the tour played a key role in putting Doral on the map," she said.
"The tour's presence in Doral fostered a strategic and mutually beneficial relationship for years, and I am truly excited about the possibility of seeing that partnership restored."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
NCSBE says 103K voters need to fix registration
The North Carolina State Board of Elections said around 103,000 people have to update their voter registration form because it is missing information. The state created this database to search your name to see if you are impacted. ALSO READ: North Carolina to send mailers to about 200,000 voters asking for missing registration info 'Ever since taking this position, I've said we are going to fix this problem and bring North Carolina into compliance with state and federal law,' NCSBE Executive Director Sam Hayes said. NCSBE Executive Director Sam Hayes said for years NCSBE used a registration form that didn't make it clear to people that you need to provide either your driver's license number or the last four digits of your social security number. You may have heard of this problem because of litigation by former State Supreme Court candidate Jefferson Griffin. He unsuccessfully attempted to discard ballots with missing information. Many of these voters had no idea there was any issue with their registration form. Voters can fix their registration forms through the DMV's website or by visiting their local board of election. In August, the state will send a letter to everyone with missing information. Voters will be able to fill out the form and mail it back in a preaddressed return envelope that is enclosed. With municipal elections approaching, election officials want voters to make sure they are in the clear. 'We've gone to great lengths to make this process as straightforward and transparent as possible,' Hayes said. If you don't fix the issue in time, you won't be turned away when you vote. But you'll have to cast a provisional ballot. The state board will then verify your information before counting it. For more information, click here. VIDEO: Part 1: The Political Beat with Ch. 9's Joe Bruno (July 20, 2025) Solve the daily Crossword
Yahoo
24 minutes ago
- Yahoo
4 former Arizona Cardinals honored in 'Actually Underrated' team
Many NFL players have fantastic careers without getting the recognition they deserve. Saints Wire's John Sigler decided to wrap up the quiet part of the offseason by putting together what he called the "Actually Underrated Team," both on offense and on defense. The concept of it goes like this: We set out to highlight the best players who weren't recognized with Pro Bowl popularity contests or coveted spots on the All-Pro teams from the Associated Press. And when possible, we tried to avoid players drafted high in the first round. Those guys are expected to start for eight or nine years and make a consistent impact. It's a different set of expectations for even a mid-round draft pick, much less a late-round lottery scratch-off or rookie free agent. On the defensive squad, four former Arizona Cardinals players were mentioned. One played only a season. Another only spent a part of a season. Two played many seasons, including one who had three different stints with the team. 'Actually Underrated' former Cardinals LB Karlos Dansby DT Corey Peters CB Tramon Williams DT Domata Peko Breaking it down Peko played 15 seasons, finishing his career after the 2020 season when he played six games for the Cardinals. He never made the Pro Bowl but started 194 games in his career and was a steady, reliable nose tackle. Williams played just one season with the Cardinals in 2017. He played 14 years in the NFL and made one Pro Bowl. Peters had a 13-year NFL career from 2010-2022. He spent 2015-2021 with the Cardinals. He had 135 total starts but did not make a Pro Bowl. Dansby was an interesting player. He never made the Pro Bowl, but statistically he could make a case for the Hall of Fame. He won't make it because he never was a Pro Bowler, but he had 20 interceptions and 43 sacks in his career. His 2013 season should have gotten more Defensive Player of the Year consideration (122 tackles, 12 tackles for loss, 6.5 sacks, 12 QB hits, an incredible 19 pass breakups and four interceptions, two of which he returned for touchdowns. In his 14-year career, he played eight for the Cardinals, from 2004-2009, then again in 2013 and again in 2017 to close out his career. Get more Cardinals and NFL coverage from Cards Wire's Jess Root and others by listening to the latest on the Rise Up, See Red podcast. Subscribe on Spotify, YouTube or Apple podcasts. This article originally appeared on Cards Wire: 4 former Arizona Cardinals honored in 'Actually Underrated' team
